Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Rhea-AI Summary

Antheia (NASDAQ:INVA) appointed Eric d'Esparbes as Chief Financial Officer effective Oct. 21, 2025. d'Esparbes will lead financial strategy and operations as Antheia advances commercialization and seeks to unlock U.S. manufacturing capabilities.

The hire follows a $56 million Series C fundraise in June 2025 and the company’s first commercial product launch in 2024. d'Esparbes brings three decades of senior finance experience, including prior CFO roles and leading an IPO in 2020.

Positive

• $56 million Series C closed in June 2025
• First commercial product launched in 2024
• CFO hire with three decades of finance leadership
• Focus on unlocking U.S. manufacturing capabilities

Negative

• None.

d'Esparbes to lead Antheia's financial strategy as the company continues its global expansion
and commercialization

MENLO PARK, Calif., Oct. 21, 2025 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer. d'Esparbes will oversee Antheia's financial strategy and operations as the company advances its next phase of commercialization and unlocks its U.S. manufacturing capabilities. His appointment comes at a critical point in Antheia's trajectory, following the company's $56 million Series C fundraise in June of this year and the launch of its first commercial product in 2024.

"As we enter our next stage of growth, Eric's deep expertise in building world-class finance teams at leading pharmaceutical and biotech organizations will be critical to our continued success," said Dr. Christina Smolke, CEO and co-founder of Antheia. "His clear vision for charting our financial strategy will support Antheia in further scaling our innovation and commercializing new products, and I am delighted to welcome him to the team."

d'Esparbes brings three decades of experience as a senior finance executive across the pharmaceutical, biotechnology, diagnostics, and energy industries. He has a proven track record building and leading finance organizations for companies with multi-billion-dollar global operations. Prior to joining Antheia, he served as Chief Financial Officer of Biora Therapeutics, where he played a key leadership role in the company's transformation into a focused biotherapeutics business and previously led its initial public offering in 2020. d'Esparbes also led the finance teams at Innoviva, Inc. (Nasdaq: INVA), Joule Unlimited, and AEI, Inc.

"Antheia's success in bringing its technology to a commercial scale is a rare and impressive feat," said Eric d'Esparbes, Chief Financial Officer of Antheia. "The company is at a pivotal juncture as it rapidly moves to increase its global production footprint, and I'm excited by the opportunity to serve our investors' interests, refine the financial framework that supports our team, and work toward our mission of ending drug shortages and transforming pharmaceutical supply chains."

About Antheia:
Antheia is the next-generation pharmaceutical ingredient producer with a mission to end drug shortages. Using advanced biosynthesis and fermentation technology, Antheia's biomanufacturing platform enables rapid, efficient, agile, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) that are critical to public health. This highly flexible approach supports the needs of a growing society and improves global access to essential medicines. Founded in 2015, Antheia has grown into a commercial stage company with its first product to market, an active customer pipeline, and near-term product launches. For more information on how Antheia is transforming pharmaceutical supply chains, visit www.antheia.bio.

Media Contact:
Mission North for Antheia
antheia@missionnorth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/antheia-appoints-eric-desparbes-as-chief-financial-officer-302589569.html

SOURCE Antheia

FAQ

Who is Eric d'Esparbes and what role did Antheia announce on Oct. 21, 2025?

Antheia named Eric d'Esparbes as its new Chief Financial Officer on Oct. 21, 2025.

How does Eric d'Esparbes' experience support Antheia (NASDAQ:INVA)?

He brings three decades of senior finance experience and prior CFO roles, including leading an IPO in 2020.

What recent financing did Antheia complete ahead of the CFO appointment?

Antheia completed a $56 million Series C fundraise in June 2025.

When did Antheia launch its first commercial product?

Antheia launched its first commercial product in 2024.

What strategic priorities will the new CFO oversee at Antheia (INVA)?

He will oversee financial strategy to support commercialization and to help unlock the company’s U.S. manufacturing capabilities.

Will the CFO appointment affect Antheia's commercialization timeline?

The company said the CFO will support scaling commercialization, but no specific timeline change was provided.